{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:03Z","timestamp":1792099563101,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["NCT01599650"],"award-info":[{"award-number":["NCT01599650"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ophtha.2016.02.030","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T21:44:18Z","timestamp":1459460658000},"page":"1332-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Individualized Stabilization Criteria\u2013Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion"],"prefix":"10.1016","volume":"123","clinical-trial-number":[{"clinical-trial-number":"nct00379795","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01599650","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5616-3579","authenticated-orcid":false,"given":"Ramin","family":"Tadayoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian M.","family":"Waldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3968-5601","authenticated-orcid":false,"given":"Heinrich","family":"Gerding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Gekkieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Mon\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2016.02.030_bib1","first-page":"1","article-title":"Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion","volume":"1","author":"Mitry","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ophtha.2016.02.030_bib2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib4","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib7","unstructured":"European Medicines Agency. Summary of Product Characteristics. Lucentis 10 mg\/ml solution for injection. Novartis 2012. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000715\/WC500043546.pdf. Accessed January 19,\u00a02015."},{"key":"10.1016\/j.ophtha.2016.02.030_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2014-305041","article-title":"Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel","volume":"99","author":"Gerding","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.02.030_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2016.01.011","article-title":"Individualized stabilization criteria-driven ranibizumab for central retinal vein occlusion: 12-month results of the CRYSTAL study","author":"Larsen","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ophtha.2007.01.010","article-title":"Interventions for branch retinal vein occlusion: an evidence-based systematic review","volume":"114","author":"McIntosh","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2415-14-7","article-title":"Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review","volume":"14","author":"Glanville","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.02.030_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00006982-200408000-00002","article-title":"Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy","volume":"24","author":"Maeshima","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.02.030_bib13","unstructured":"Koh A, Gekkiev B, Das Gupta A, Lacey S. Ranibizumab treatment and visual acuity outcomes in the presence or absence of pigment epithelium detachments: an interim analysis of the LUMINOUS study. Abstract number: 2175197. Presented at: 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 3\u20137, 2015; Denver, Colorado."},{"key":"10.1016\/j.ophtha.2016.02.030_bib14","unstructured":"Lotery A, Bleier J, Regnier S. Treatment patterns for patients starting anti-VEGF therapy for retinal vein occlusion in US clinical practice. Poster PO563 presented at the AAO Annual Meeting, October 18\u201321, 2014, Chicago, Illinois."},{"key":"10.1016\/j.ophtha.2016.02.030_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","article-title":"Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration","volume":"114","author":"Boyer","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.02.030_bib18","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"Bressler","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.02.030_bib19","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/eye.2011.224","article-title":"Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6\/12","volume":"25","author":"Williams","year":"2011","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2016.02.030_bib20","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.02.030_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.eye.6703053","article-title":"Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss","volume":"23","author":"Arias","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2016.02.030_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0008-4182(05)80074-2","article-title":"Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration","volume":"40","author":"Oliver-Fernandez","year":"2005","journal-title":"Can J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016002839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016002839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T16:41:24Z","timestamp":1666543284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016002839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0161642016002839"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.030","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726262505.793544724","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized Stabilization Criteria\u2013Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license ?(<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/?creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}